WuXi Biologics (Cayman) Profit Margin

The latest profit margin for WXIBF is 21.07% as of June 2026. That compares with 20.15% in the prior-year period — up 4.6% year over year. That is above the Healthcare sector average of 9.48%. Investors often review this figure alongside WuXi Biologics (Cayman)'s historical trend and sector peers before judging valuation or financial health.

Over the past year, WXIBF's profit margin moved from 20.15% to 21.07% — a 4.6% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in WuXi Biologics (Cayman)'s valuation or profitability profile.

Against Healthcare companies, WXIBF currently prints 21.07% for profit margin, while the sector average sits near 9.48%. That is roughly 122.3% above the sector mean. Large gaps often invite a closer look at WuXi Biologics (Cayman)'s growth, margins, and balance sheet.

Profit Margin shows how effectively WuXi Biologics (Cayman) converts resources into returns. At 21.07%, WXIBF may look efficient or underperforming depending on peer benchmarks and trend direction. That compares with 20.15% in the prior-year period — up 4.6% year over year. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting WXIBF's profit margin (21.07%), review year-over-year change from 20.15%, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.